Paromomycin

Generic Name: Paromomycin

Brand Names: Humatin

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₄₅N_₅O_₁₄

CAS Number: 7542-37-2

Unique Ingredient Identifier: 61JJC8N5ZK

Background: An oligosaccharide antibiotic produced by various streptomyces. [PubChem]

Indication: For the treatment of acute and chronic intestinal amebiasis (it is not effective in extraintestinal amebiasis). Also for the management of hepatic coma as adjunctive therapy.

Associated Conditions: Dientamoeba fragilis infection, Hepatic coma, Acute Intestinal amebiasis, Chronic Intestinal amebiasis

Associated Therapies: -

Clinical Trials

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

Phase 2

Recruiting

Conditions: Primary Visceral Leishmaniasis

Interventions: Drug: sodium stibogluconate
Drug: LXE408
Drug: Paromomycin

First Posted Date: 2023-07-24

Last Posted Date: 2024-11-08

Lead Sponsor: Drugs for Neglected Diseases

Target Recruit Count: 52

Registration Number: NCT05957978

Locations: 🇪🇹
University of Gondar, Gondar, Ethiopia

Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis

Phase 2

Completed

Conditions: Cutaneous Leishmaniasis, American

Interventions: Drug: Miltefosine and Paromomycin
Drug: paromomycin
Drug: miltefosine

First Posted Date: 2019-02-04

Last Posted Date: 2021-02-02

Lead Sponsor: Fundacion Nacional de Dermatologia

Target Recruit Count: 120

Registration Number: NCT03829917

Locations: 🇧🇴
Hopital, Dermatologico, Jorochito, SC, Bolivia

Short Course Regimens for Treatment of PKDL (Sudan)

Phase 2

Conditions: PKDL - Post-Kala-Azar Dermal Leishmanioid

Interventions: Drug: Paromomycin
Drug: Ambisome
Drug: Miltefosine

First Posted Date: 2018-01-17

Last Posted Date: 2020-01-18

Lead Sponsor: Drugs for Neglected Diseases

Target Recruit Count: 110

Registration Number: NCT03399955

Locations: 🇸🇩
Prof. Elhassan Centre for tropical Medicine, Doka, Gedaref, Sudan

Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

Phase 3

Completed

Conditions: Visceral Leishmaniasis

Interventions: Drug: Miltefosine
Drug: Paromomycin
Drug: Sodium stibogluconate

First Posted Date: 2017-04-26

Last Posted Date: 2024-02-29

Lead Sponsor: Drugs for Neglected Diseases

Target Recruit Count: 439

Registration Number: NCT03129646

Locations: 🇪🇹
Abdurafi MSF Health Center, Ābderafī, Amhara, Ethiopia
🇸🇩
El Hassan Centre for Tropical Medicine, Doka, Gedaref, Sudan
🇰🇪
Kacheliba Hospital, Kapenguria, West Pokot, Kenya

and more 4 locations

Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama

Phase 3

Completed

Conditions: Cutaneous Leishmaniasis

Interventions: Drug: WR 279,396
Drug: Paromomycin

First Posted Date: 2013-02-13

Last Posted Date: 2018-02-14

Lead Sponsor: U.S. Army Medical Research and Development Command

Target Recruit Count: 399

Registration Number: NCT01790659

Locations: 🇵🇦
Instituto Conmemorativo Gorgas de Estudios de la Salud,, Panama City, Panama

Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis

Conditions: Leishmaniasis, Cutaneous

First Posted Date: 2012-07-17

Last Posted Date: 2020-05-15

Lead Sponsor: U.S. Army Medical Research and Development Command

Registration Number: NCT01641796

Locations: 🇺🇸
Military Treatment Facilities, Multiple Locations, Maryland, United States
🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States

An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis

Phase 3

Completed

Conditions: Visceral Leishmaniasis

Interventions: Drug: Paromomycin

First Posted Date: 2008-03-05

Last Posted Date: 2008-09-12

Lead Sponsor: Banaras Hindu University

Target Recruit Count: 329

Registration Number: NCT00629031

Locations: 🇮🇳
Kala-azar Medical Research Center, Rambag Road, Varanasi, India

Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis

Phase 4

Completed

Conditions: Visceral Leishmaniasis

Interventions: Drug: Paromomycin sulfate

First Posted Date: 2008-01-30

Last Posted Date: 2014-10-03

Lead Sponsor: PATH

Target Recruit Count: 2000

Registration Number: NCT00604955

Locations: 🇮🇳
Rajendra Memorial Research Institute of Medical Sciences, Agam Kuan, Patna, Bihar, India
🇮🇳
Shrimati Hazari Maternity and Medical Care, Azad Nagar, Balua Tal, Motihari, Bihar, India
🇮🇳
Research Centre for Diabetes, Hypertension and Obesity, Bengali Tola, Samastipur, Bihar, India

and more 4 locations

Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis

Phase 3

Completed

Conditions: Visceral Leishmaniasis

First Posted Date: 2005-09-22

Last Posted Date: 2014-10-03

Lead Sponsor: PATH

Target Recruit Count: 667

Registration Number: NCT00216346

Locations: 🇮🇳
Rajendra Memorial Research Institute of Medical Sciences (ICMR), Agam Kuan, Patna, Bihar, India
🇮🇳
Kalazar Research Centre, Patna, Bihar, India
🇮🇳
Kala-azar Medical Research Centre, Rambagh Road Muzaffarpur, Bihar, India

A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3

Phase 2

Completed

Conditions: Cryptosporidiosis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 68

Registration Number: NCT00000771

Locations: 🇵🇷
Puerto Rico-AIDS CRS, San Juan, Puerto Rico
🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸
Univ. of Miami AIDS CRS, Miami, Florida, United States

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy